PMID- 22024351
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111123
LR  - 20211020
IS  - 1476-8518 (Electronic)
IS  - 1476-8518 (Linking)
VI  - 9
DP  - 2011 Oct 24
TI  - Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with 
      an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell 
      lung cancer (NSCLC) patients.
PG  - 7
LID - 10.1186/1476-8518-9-7 [doi]
AB  - The prognosis of patients with advanced non small cell lung (NSCLC) cancer 
      remains dismal. Epidermal Growth Factor Receptor is over-expressed in many 
      epithelial derived tumors and its role in the development and progression of 
      NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed 
      by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier 
      protein, P64K from Neisseria Meningitides. The vaccine is intended to induce 
      antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF 
      has been evaluated so far in more than 1000 advanced NSCLC patients, as second 
      line therapy. Two separate studies were compared to assess the impact of high 
      dose vaccination at multiple anatomic sites in terms of immunogenicity, safety 
      and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical 
      trials, patients started vaccination 1 month after finishing first line 
      chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high dose) was very 
      safe. The most frequent adverse events were grade 1 or 2 injection site 
      reactions, fever, headache and vomiting. Patients had a trend toward higher 
      antibody response. The percent of very good responders significantly augmented 
      and there was a faster decrease of circulating EGF. All vaccinated patients and 
      those classified as good responders immunized with high dose at 4 sites, had a 
      large tendency to improved survival.
FAU - Rodriguez, Pedro C
AU  - Rodriguez PC
AD  - Center of Molecular Immunology, PO Box: 16040, Havana 11600, Cuba. 
      camilo@cim.sld.cu.
FAU - Neninger, Elia
AU  - Neninger E
FAU - Garcia, Beatriz
AU  - Garcia B
FAU - Popa, Xitlally
AU  - Popa X
FAU - Viada, Carmen
AU  - Viada C
FAU - Luaces, Patricia
AU  - Luaces P
FAU - Gonzalez, Gisela
AU  - Gonzalez G
FAU - Lage, Agustin
AU  - Lage A
FAU - Montero, Enrique
AU  - Montero E
FAU - Crombet, Tania
AU  - Crombet T
LA  - eng
PT  - Journal Article
DEP - 20111024
PL  - England
TA  - J Immune Based Ther Vaccines
JT  - Journal of immune based therapies and vaccines
JID - 101152206
PMC - PMC3215653
EDAT- 2011/10/26 06:00
MHDA- 2011/10/26 06:01
PMCR- 2011/10/24
CRDT- 2011/10/26 06:00
PHST- 2011/04/28 00:00 [received]
PHST- 2011/10/24 00:00 [accepted]
PHST- 2011/10/26 06:00 [entrez]
PHST- 2011/10/26 06:00 [pubmed]
PHST- 2011/10/26 06:01 [medline]
PHST- 2011/10/24 00:00 [pmc-release]
AID - 1476-8518-9-7 [pii]
AID - 10.1186/1476-8518-9-7 [doi]
PST - epublish
SO  - J Immune Based Ther Vaccines. 2011 Oct 24;9:7. doi: 10.1186/1476-8518-9-7.